IXICO plc New contract with top 10 pharmaceutical company (8878N)

TIDMIXI

RNS Number : 8878N

IXICO plc

14 May 2018

14 May 2018

IXICO plc

("IXICO" or the "Company")

New contract with top 10 pharmaceutical company

Providing specialist imaging clinical trials services in Huntington's disease

IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announced that it has signed a new contract with a top 10 pharmaceutical company, further expanding its relationship with one of its existing clients. The contract value is GBP1.0m over a three year term, with study planning and site set-up activities starting in the next few months.

IXICO will provide its technology-enabled imaging services in a natural history study of people with early manifest Huntington's disease ("HD") to observe the natural progression of the disease. IXICO will use its TrialTracker(TM) digital platform to standardise the acquisition and collection of MRI scans, including advanced functional MR imaging, from centres across Europe and North America. IXICO will also apply its proprietary image analysis algorithms, together with in-licenced algorithms from leading academic centres, to measure neurological changes in study participants.

HD is a rare genetic neurodegenerative disorder that affects movement, cognition and behaviour. This is an area of significant unmet medical need as there are currently no effective marketed treatments. IXICO was first involved in HD studies in 2007, supporting some of the early observational studies led by academic centres in Europe and North America, which characterised the progression of the disease. Since that date IXICO has been successful in providing its clinical trials services to pharmaceutical and biopharmaceutical companies working in this important area of clinical development.

Giulio Cerroni, Chief Executive of IXICO, said: "Today's announcement continues IXICO's successful track record in providing neuroimaging clinical trial services for Huntington's disease, representing our third new contract in this therapeutic area in the current financial year. I am delighted that we continue to win new business with existing clients which I believe demonstrates the value placed by our customers on the unique combination of technologies and scientific expertise that we provide."

For further information please contact:

 
 IXICO plc 
  Giulio Cerroni, Chief Executive Officer        Tel: [phone] 
  Susan Lowther, Chief Financial Officer         7499 
 
 Shore Capital (Nomad and Broker)              Tel: [phone] 
  Edward Mansfield / Anita Ghanekar / Daniel    4090 
  Bush 
 
 FTI Consulting Limited (Investor Relations)   Tel: [phone] 
  Simon Conway/Mo Noonan                        1000 
 

About IXICO

IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

CNTGRGDUXSBBGID

(END) Dow Jones Newswires

May 14, 2018 02:00 ET (06:00 GMT)